Safety profile of linezolid in patients with bone marrow suppression after chemotherapy for acute myeloid leukemia
10.16718/j.1009-7708.2025.05.007
- VernacularTitle:急性髓系白血病化疗后骨髓抑制患者利奈唑胺使用安全性分析
- Author:
Yi CUI
1
;
Ru LIAO
;
Peixi ZHAO
;
Haiyan DONG
Author Information
1. 西安交通大学第一附属医院药学部,西安 710061;陕西省肿瘤医院药学部
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
linezolid;
bone marrow suppression;
thrombocytopenia;
safety
- From:
Chinese Journal of Infection and Chemotherapy
2025;25(5):523-529
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of linezolid on platelets in patients with acute myeloid leukemia(AML)and analyze the safety profile of linezolid by comparing the platelet count and bleeding risk of linezolid during bone marrow suppression in patients after chemotherapy for AML.Methods A retrospective study was conducted on patients who underwent chemotherapy for AML in a tertiary hospital from January 2020 to November 2024.The patients treated with linezolid and those not receiving linezolid were matched in a 1∶2 ratio.The safety of linezolid during bone marrow suppression after chemotherapy for AML was analyzed in terms of platelet count＜20×109/L,＜50×109/L,minimum platelet count,total platelet transfusion volume,and clinical bleeding events.Results A total of 126 patients were enrolled,including 42 patients receiving linezolid and 84 patients not receiving linezolid.There was no significant difference between linezolid group and control group in the days for platelet count＜20×109/Land＜50×109/L.No life-threatening severe bleeding events were reported in either group.The time to platelet recovery and time to platelet count increase prolonged significantly in patients who received linezolid treatment for more than 7 days during bone marrow suppression.Albumin＜35 g/L may prolong the time to platelet count increase.Conclusions This study suggests that short-term use of linezolid for not more than 7 days is safe during bone marrow suppression in patients after chemotherapy for AML.When linezolid is used for more than 7 days,the time required for platelet recovery and platelet count increase will be significantly prolonged.In cases of albumin＜35 g/L,the time required for platelet count increase may be prolonged.These findings can inform clinical decision-making and help optimize infection management strategies for AML patients.
